SteriPlas to be presented at the DFSG conference
Adtec looks forward to supporting Ms Jemma Cruickshank, Antimicrobial Pharmacy Technician from Kettering General Hospital NHS Foundation Trust, at the Diabetic Foot Study Group (DFSG) conference in September.
Jemma has been invited to present the “Retrospective review of the use of argon cold plasma therapy in non-healing diabetic foot ulcers over a 3-year period within a DGH Diabetic Foot MDT Service” at the conference.
Her presentation will include the strong benefits of the SteriPlas on chronic and large diabetic foot ulcers prone to biofilm infections.
The abstract for this presentation can be found here: https://distribute.m-anage.com/from.storage?image=erIsXlaDuNOv64Tv4JyKY6XW3cI1HigkZNgT5cOgYv7Vzt_UHvGbDPesijzVroVO0
For more information about our SteriPlas Premium Cold Plasma medical device, send us an email info@adtecplasma.com
What makes our SteriPlas safe and effective?
What makes our SteriPlas Premium Cold Plasma safe and effective?
Adtec has been the global leader of Cold Plasma medicine, having developed Cold Plasma products for over 20 years and being the first company worldwide to conduct clinical trials on wounds. In total, Adtec boasts over 80+ clinical trials and studies with no side effects reported.
Whilst there are many forms of Cold Plasmas on the market, our SteriPlas Cold Plasma is dense and slowly propelled towards the treatment site enabling bacterial destruction in deep and hard to reach infection areas. The argon Cold Plasma is microwave, 2.45GHz generated using crucial components within the body of the medical device. This is why it is larger in size but at the advantage of delivering reliable and consistent results and easily tackles complicated biofilm issues within chronic infections unlike the other variations of Cold Plasma on the market. This is also why our clinical evidence is often cited by other Cold Plasma manufacturers as our promising results far outweigh the results achieved by Cold Plasma devices with different plasma designs.
To learn more about our strengths and benefits, contact us at info@adtecplasma.com
Leading the way in Cold Plasma Medicine
The antibiofilm properties of the SteriPlas has been widely documented across our 80+ clinical trials and studies. It is being widely used to treat a multitude of infection conditions such as Diabetic Foot Ulcers, Sternal Wounds and LVAD infections in the UK, EU and SE Asia. Helping to significantly reduce morbidity, mortality, amputation and bed occupancy rates, the SteriPlas has been transforming modern medicine by simplifying and accelerating the way these chronic and non-healing wounds are treated. We have also documented the significant cost saving benefits of using the SteriPlas Premium Cold Plasma all with the added benefit of no side effects due to its safe, microwave 2.45GHz argon plasma generation.
To learn more about the benefits we can bring you, contact us at info@adtecplasma.com
Upcoming Exhibitions for 2024
Adtec looks forward to exhibiting at the Diabetic Foot Study Group (DFSG) conference between 6-8 September and the European Mechanical Support Summit (EUMS) conference between 11-14 September. At both conferences, we will have our SteriPlas Premium Cold Plasma medical device on our booth for a live demonstration. The SteriPlas boasts a strong clinical evidence collection of 80+ clinical trials and studies across a multitude of infection conditions.
To better understand our medical device and the positive imprint we have made on the severe infection conditions, please visit our booth during the two shows to see the SteriPlas in person.
Day 2 of the Malvern Diabetic Foot Conference
Day 2 of the Malvern Diabetic Foot Conference 2024. Don't forget to visit us to see how Premium Cold Plasma SteriPlas has healed chronic diabetic foot ulcers.
Day 2 of EWMA 2024
Day 2 of the European Wound Management Association (EWMA) exhibition. Visit us at booth G70 to see our Premium Cold Plasma live in action. With the strongest clinical efficacy for the infection management in wounds, surgical site infections and medical dermatology.
Day 1 of EWMA 2024
Day 1 of the European Wound Management Association (EWMA) exhibition. We have enjoyed catching up with friends and meeting new people interested in our Premium Cold Plasma medical device. Our Clinical Bibliography of 80+ clinical trials and studies puts us at the forefront of Cold Plasma Medicine for wounds, surgical site infections and medical dermatology. Visit us at booth G70 to learn more.
EWMA 2024
We look forward to exhibiting at the European Wound Management Association (EWMA) exhibition next week. Positioned at booth #G70, our Premium Cold Plasma medical device, the SteriPlas, will be featured to the public. Adtec Healthcare Cold Plasma company can boast of having very strong clinical trials data amongst a total of 80+ peer reviewed studies. Our medical device has proven anti-biofilm efficacy in chronic infections within wounds, surgical site infections and medical dermatology conditions.
Day 1 of the ISHLT
An exciting start to the ISHLT 2024 show. Our SteriPlas Premium Cold Plasma medical device is being widely spoken about throughout the sessions and we welcome you to visit our booth no.12 to learn more.
Adtec to exhibit at the ISHLT show
We are excited to be exhibiting at the ISHLT show next week. Our team will be onsite at booth no. 12 ready to welcome you and introduce you to our SteriPlas Premium Cold Plasma medical device used for the treatment of LVAD infections complicated with biofilm. Many of our customers will also be at the show who would be happy to give you a demonstration of our SteriPlas or to explain the strong clinical efficacy observed when using our medical device.
If you would like to secure a meeting in advance, please contact us at info@adtecplasma.com